Literature DB >> 27592547

Metastatic Cell Dormancy and Re-activation: An Overview on Series of Molecular Events Critical for Cancer Relapse.

Gyorgyi Muzes1, Ferenc Sipos.   

Abstract

Cancer patients, though frequently entering complete remission after successful surgery, and/or irradiation, and chemotherapy years or even decades later may exhibit overt metastases and aggressive, mostly fatal recurrence on the basis of clinically silent persistence of disseminated tumor cells. Cellular dormancy is a mode of hibernation/ inactivity caused by a temporary mitotic arrest. It represents the critical phenomenon of latency making metastatic cancer cells highly refractory to conventional therapies. Regarding host-tumor interactions a broad range of dynamic, interrelated molecular events may influence the dormancy state of quiescence, like regulators of cell cycle arrest, stress signaling pathways, autophagy, microenvironmental, angiogenic and immunologic factors, genetic and epigenetic effects. Nonetheless, the underlying mechanisms are still poorly understood. Moreover, a distinct subset of circulating and disseminated cancer cells exhibits stem cell-like properties with direct tumor-provoking and metastatis-initiating capacity, being at least partly responsible for the specific dormancy features. In residual disease a future more detailed molecular and phenotypic characterization of disseminated tumor cells could represent the prerequisite not only for prognostic and staging purposes, but for a specific design of therapeutic targeting, as well. By understanding the elusive dormancy signatures of tumor cells, their cell- and context (microenvironment)-dependent modulation should provide novel potential therapeutic approaches to avoid or overcome metastatic cancer relapse. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Cancer dormancy; autophagy; cell adaptation; metastasis; microenvironment; quiescence; stem cell; stress signals

Mesh:

Year:  2017        PMID: 27592547     DOI: 10.2174/1871520616666160901145857

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  5 in total

1.  Identification of Genes Regulating Breast Cancer Dormancy in 3D Bone Endosteal Niche Cultures.

Authors:  Julie McGrath; Louis Panzica; Ryan Ransom; Henry G Withers; Irwin H Gelman
Journal:  Mol Cancer Res       Date:  2019-01-16       Impact factor: 5.852

2.  PCSK9 Axis-Targeting Pseurotin A as a Novel Prostate Cancer Recurrence Suppressor Lead.

Authors:  Khaldoun S Abdelwahed; Abu Bakar Siddique; Mohammed H Qusa; Judy Ann King; Soumaya Souid; Zakaria Y Abd Elmageed; Khalid A El Sayed
Journal:  ACS Pharmacol Transl Sci       Date:  2021-10-05

Review 3.  Hibernating astronauts-science or fiction?

Authors:  A Choukèr; Jürgen Bereiter-Hahn; D Singer; G Heldmaier
Journal:  Pflugers Arch       Date:  2018-12-19       Impact factor: 3.657

4.  Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching.

Authors:  Chen Chen; Shujie Zhao; Xiangru Zhao; Lin Cao; Anand Karnad; Addanki P Kumar; James W Freeman
Journal:  Cell Death Dis       Date:  2022-08-05       Impact factor: 9.685

5.  Stem-Mesenchymal Signature Cell Genes Detected in Heterogeneous Circulating Melanoma Cells Correlate With Disease Stage in Melanoma Patients.

Authors:  Maria Cristina Rapanotti; Elena Campione; Tara Mayte Suarez Viguria; Giulia Spallone; Gaetana Costanza; Piero Rossi; Augusto Orlandi; Piera Valenti; Sergio Bernardini; Luca Bianchi
Journal:  Front Mol Biosci       Date:  2020-05-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.